作者
Eva Havrdova, Steven Galetta, Michael Hutchinson, Dusan Stefoski, David Bates, Chris H Polman, Paul W O'Connor, Gavin Giovannoni, J Theodore Phillips, Fred D Lublin, Amy Pace, Richard Kim, Robert Hyde
发表日期
2009/3/1
期刊
The Lancet Neurology
卷号
8
期号
3
页码范围
254-260
出版商
Elsevier
简介
Background
The efficacy of natalizumab on clinical and radiological measures in the phase III Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study has prompted the investigation of whether natalizumab can increase the proportion of patients with relapsing-remitting multiple sclerosis who do not have disease activity.
Methods
Post-hoc analyses of data from the AFFIRM study were done to determine the effects of natalizumab compared with placebo on the proportion of patients who were free of disease activity over 2 years. Absence of disease activity was defined as no activity on clinical measures (no relapses and no sustained disability progression), radiological measures (no gadolinium-enhancing lesions and no new or enlarging T2-hyperintense lesions on cranial MRI), or a composite of the two.
Findings
383 (64%) of 596 patients taking natalizumab and 117 (39%) of 301 …
引用总数
学术搜索中的文章
E Havrdova, S Galetta, M Hutchinson, D Stefoski… - The Lancet Neurology, 2009